Sino Biopharmaceutical’s Breakthrough in Lung Cancer Treatment

The latest update is out from Sino Biopharmaceutical ( (HK:1177) ).

Sino Biopharmaceutical has announced positive results from its Phase III clinical study of Benmelstobart Injection combined with chemotherapy and Anlotinib for treating advanced squamous non-small cell lung cancer (sq-NSCLC). The study, presented at the 2025 ASCO Annual Meeting, showed a significant improvement in median progression-free survival and overall response rates compared to the control group. This breakthrough could potentially change the treatment landscape for sq-NSCLC, offering new hope for patients with limited options.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$4.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical is a company operating in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs. Its primary products include treatments for various diseases, with a market focus on addressing unmet clinical needs.

Average Trading Volume: 103,149,000

Technical Sentiment Signal: Buy

Current Market Cap: HK$75.33B

For a thorough assessment of 1177 stock, go to TipRanks’ Stock Analysis page.